5 Sep 2022 11:12 am
That is of course one of the trials included in the link I presented.
https://c19ivermectin.com/lim.html
A trial of "490 late stage (>65% lung change chest radiography at baseline) hospitalized patients in Malaysia", further demonstrating once again why early treatment is important in treatment of COVID.
In other words, another designed to fail study. Yet even still:
"Mortality was 1.2% for ivermectin vs. 4% for control."
It just didn't reach statistical significance over 490 subjects.
So even in late treatment, which group would you have preferred to have been in?
"The mortality reduction is consistent with the results from all trials to date. While not reaching the significance threshold with the specified test, Bayesian analysis shows a 97% probability that ivermectin reduces mortality [normanfenton.com]. Authors describe the mortality results as "similar" and they are not mentioned in the visual abstract or the conclusion, suggesting substantial investigator bias with a preference for a null result."